
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Income Statement
Earnings Waterfall
Alnylam Pharmaceuticals Inc
Revenue
|
2.2B
USD
|
Cost of Revenue
|
-323.4m
USD
|
Gross Profit
|
1.9B
USD
|
Operating Expenses
|
-2.1B
USD
|
Operating Income
|
-176.9m
USD
|
Other Expenses
|
-101.3m
USD
|
Net Income
|
-278.2m
USD
|
Income Statement
Alnylam Pharmaceuticals Inc
Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||||||||||||
Revenue |
51
N/A
|
61
+20%
|
62
+2%
|
58
-8%
|
41
-29%
|
30
-27%
|
30
N/A
|
37
+25%
|
47
+27%
|
59
+25%
|
66
+12%
|
70
+5%
|
90
+29%
|
93
+3%
|
107
+15%
|
92
-14%
|
75
-18%
|
86
+15%
|
101
+17%
|
169
+67%
|
220
+30%
|
286
+30%
|
345
+21%
|
401
+16%
|
493
+23%
|
571
+16%
|
688
+20%
|
749
+9%
|
844
+13%
|
880
+4%
|
884
+0%
|
961
+9%
|
1 037
+8%
|
1 143
+10%
|
1 237
+8%
|
1 724
+39%
|
1 828
+6%
|
2 003
+10%
|
2 344
+17%
|
2 095
-11%
|
2 248
+7%
|
|
Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(2)
|
(5)
|
(9)
|
(15)
|
(25)
|
(35)
|
(51)
|
(67)
|
(78)
|
(96)
|
(115)
|
(126)
|
(140)
|
(145)
|
(147)
|
(155)
|
(169)
|
(188)
|
(233)
|
(276)
|
(310)
|
(322)
|
(305)
|
(306)
|
(323)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
73
+3 747%
|
51
-30%
|
92
+79%
|
155
+69%
|
195
+26%
|
251
+29%
|
295
+17%
|
334
+13%
|
415
+24%
|
475
+15%
|
573
+21%
|
624
+9%
|
704
+13%
|
735
+4%
|
738
+0%
|
806
+9%
|
869
+8%
|
955
+10%
|
1 005
+5%
|
1 448
+44%
|
1 518
+5%
|
1 682
+11%
|
2 040
+21%
|
1 788
-12%
|
1 925
+8%
|
|
Operating Income | ||||||||||||||||||||||||||||||||||||||||||
Operating Expenses |
(456)
|
(249)
|
(278)
|
(307)
|
(337)
|
(384)
|
(403)
|
(439)
|
(472)
|
(480)
|
(515)
|
(538)
|
(590)
|
(634)
|
(720)
|
(833)
|
(888)
|
(917)
|
(992)
|
(1 016)
|
(1 134)
|
(1 212)
|
(1 218)
|
(1 266)
|
(1 243)
|
(1 280)
|
(1 325)
|
(1 332)
|
(1 413)
|
(1 404)
|
(1 452)
|
(1 597)
|
(1 654)
|
(1 820)
|
(1 908)
|
(1 802)
|
(1 800)
|
(1 858)
|
(1 937)
|
(1 977)
|
(2 102)
|
|
Selling, General & Administrative |
(45)
|
(48)
|
(51)
|
(58)
|
(61)
|
(69)
|
(72)
|
(79)
|
(89)
|
(107)
|
(135)
|
(160)
|
(199)
|
(233)
|
(272)
|
(341)
|
(382)
|
(400)
|
(428)
|
(432)
|
(479)
|
(516)
|
(531)
|
(579)
|
(588)
|
(609)
|
(626)
|
(601)
|
(621)
|
(628)
|
(653)
|
(747)
|
(771)
|
(800)
|
(845)
|
(808)
|
(796)
|
(823)
|
(857)
|
(878)
|
(976)
|
|
Research & Development |
(411)
|
(201)
|
(227)
|
(249)
|
(277)
|
(315)
|
(331)
|
(360)
|
(382)
|
(373)
|
(381)
|
(378)
|
(391)
|
(401)
|
(448)
|
(492)
|
(505)
|
(538)
|
(564)
|
(585)
|
(655)
|
(696)
|
(687)
|
(688)
|
(655)
|
(671)
|
(699)
|
(732)
|
(792)
|
(776)
|
(799)
|
(850)
|
(883)
|
(944)
|
(987)
|
(994)
|
(1 004)
|
(1 035)
|
(1 080)
|
(1 098)
|
(1 126)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
20
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(76)
|
(76)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(405)
N/A
|
(188)
+54%
|
(216)
-15%
|
(249)
-15%
|
(296)
-19%
|
(354)
-19%
|
(373)
-6%
|
(402)
-8%
|
(425)
-6%
|
(421)
+1%
|
(449)
-7%
|
(468)
-4%
|
(500)
-7%
|
(541)
-8%
|
(613)
-13%
|
(742)
-21%
|
(815)
-10%
|
(836)
-3%
|
(900)
-8%
|
(862)
+4%
|
(939)
-9%
|
(961)
-2%
|
(924)
+4%
|
(932)
-1%
|
(828)
+11%
|
(805)
+3%
|
(752)
+7%
|
(708)
+6%
|
(709)
0%
|
(669)
+6%
|
(715)
-7%
|
(791)
-11%
|
(785)
+1%
|
(865)
-10%
|
(903)
-4%
|
(354)
+61%
|
(282)
+20%
|
(176)
+38%
|
103
N/A
|
(188)
N/A
|
(177)
+6%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
Interest Income Expense |
3
|
3
|
4
|
5
|
6
|
7
|
7
|
8
|
8
|
9
|
9
|
10
|
12
|
16
|
19
|
23
|
29
|
31
|
34
|
37
|
33
|
32
|
(1)
|
(38)
|
(73)
|
(82)
|
(99)
|
(91)
|
(124)
|
(207)
|
(239)
|
(287)
|
(259)
|
(192)
|
(156)
|
(143)
|
(134)
|
(129)
|
(152)
|
(139)
|
(194)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
21
|
21
|
21
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(77)
|
(77)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
2
|
2
|
2
|
1
|
0
|
5
|
6
|
6
|
6
|
(2)
|
(3)
|
(4)
|
(3)
|
0
|
3
|
6
|
4
|
4
|
11
|
5
|
21
|
44
|
80
|
82
|
46
|
13
|
(32)
|
(36)
|
(19)
|
(16)
|
(25)
|
(26)
|
(6)
|
(3)
|
(1)
|
(5)
|
(18)
|
(20)
|
(12)
|
6
|
(7)
|
|
Pre-Tax Income |
(401)
N/A
|
(183)
+54%
|
(210)
-15%
|
(243)
-16%
|
(290)
-19%
|
(342)
-18%
|
(361)
-5%
|
(388)
-8%
|
(410)
-6%
|
(414)
-1%
|
(443)
-7%
|
(462)
-4%
|
(491)
-6%
|
(525)
-7%
|
(570)
-9%
|
(692)
-21%
|
(761)
-10%
|
(801)
-5%
|
(856)
-7%
|
(820)
+4%
|
(885)
-8%
|
(886)
0%
|
(845)
+5%
|
(889)
-5%
|
(856)
+4%
|
(873)
-2%
|
(884)
-1%
|
(835)
+5%
|
(852)
-2%
|
(892)
-5%
|
(979)
-10%
|
(1 180)
-21%
|
(1 127)
+5%
|
(1 060)
+6%
|
(1 060)
+0%
|
(503)
+53%
|
(434)
+14%
|
(325)
+25%
|
(62)
+81%
|
(321)
-420%
|
(377)
-18%
|
|
Net Income | ||||||||||||||||||||||||||||||||||||||||||
Tax Provision |
40
|
23
|
22
|
22
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(3)
|
(2)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(3)
|
(2)
|
(1)
|
(1)
|
(2)
|
(2)
|
(4)
|
(5)
|
(4)
|
(7)
|
(7)
|
(7)
|
(11)
|
(11)
|
99
|
|
Income from Continuing Operations |
(360)
|
(160)
|
(188)
|
(221)
|
(290)
|
(342)
|
(361)
|
(388)
|
(410)
|
(414)
|
(443)
|
(462)
|
(491)
|
(526)
|
(571)
|
(693)
|
(762)
|
(802)
|
(858)
|
(821)
|
(886)
|
(886)
|
(846)
|
(891)
|
(858)
|
(876)
|
(887)
|
(838)
|
(853)
|
(893)
|
(981)
|
(1 182)
|
(1 131)
|
(1 065)
|
(1 064)
|
(510)
|
(440)
|
(332)
|
(73)
|
(332)
|
(278)
|
|
Net Income (Common) |
(360)
N/A
|
(160)
+56%
|
(188)
-17%
|
(221)
-17%
|
(290)
-31%
|
(342)
-18%
|
(361)
-5%
|
(388)
-8%
|
(410)
-6%
|
(414)
-1%
|
(443)
-7%
|
(462)
-4%
|
(491)
-6%
|
(525)
-7%
|
(570)
-9%
|
(692)
-21%
|
(762)
-10%
|
(802)
-5%
|
(858)
-7%
|
(821)
+4%
|
(886)
-8%
|
(886)
0%
|
(846)
+5%
|
(891)
-5%
|
(858)
+4%
|
(876)
-2%
|
(887)
-1%
|
(838)
+6%
|
(853)
-2%
|
(893)
-5%
|
(981)
-10%
|
(1 182)
-21%
|
(1 131)
+4%
|
(1 065)
+6%
|
(1 064)
+0%
|
(510)
+52%
|
(440)
+14%
|
(332)
+25%
|
(73)
+78%
|
(332)
-356%
|
(278)
+16%
|
|
EPS (Diluted) |
-4.68
N/A
|
-1.95
+58%
|
-2.22
-14%
|
-2.6
-17%
|
-3.45
-33%
|
-4.01
-16%
|
-4.21
-5%
|
-4.54
-8%
|
-4.79
-6%
|
-4.83
-1%
|
-5.02
-4%
|
-5.02
N/A
|
-5.42
-8%
|
-5.24
+3%
|
-5.67
-8%
|
-6.86
-21%
|
-7.58
-10%
|
-7.61
0%
|
-7.9
-4%
|
-7.55
+4%
|
-8.11
-7%
|
-7.86
+3%
|
-7.36
+6%
|
-7.68
-4%
|
-7.46
+3%
|
-7.48
0%
|
-7.52
-1%
|
-7.03
+7%
|
-7.2
-2%
|
-7.41
-3%
|
-8.11
-9%
|
-9.67
-19%
|
-9.3
+4%
|
-8.58
+8%
|
-8.52
+1%
|
-3.88
+54%
|
-3.52
+9%
|
-2.63
+25%
|
-0.57
+78%
|
-2.58
-353%
|
-2.18
+16%
|